

CBE ID

0071

Title

Persistence of Beta-Blocker Treatment After a Heart Attack

Endorsement Status

Endorsed by Extension

Is Under Review

No

Next Maintenance Cycle

Fall 2027

Previous Endorsement Cycle

Fall 2019

Initial Endorsement

Sun, 08/09/2009 - 20:00

Steward

National Committee for Quality Assurance

1.0 New or Maintenance

Maintenance

1.1 Measure Structure

Single Measure

1.3 Electronic Clinical Quality Measure (eCQM)

No

1.6 Measure Description

The percentage of patient's 18 years of age and older during the measurement year who were hospitalized and discharged from July 1 of the year prior to the measurement year to June 30 of the measurement year with a diagnosis of acute myocardial infarction (AMI) and who received persistent beta-blocker treatment for six months after discharge.

1.7 Measure Type

Intermediate Outcome

1.8 Level of Analysis

Health Plan

1.13 Data Dictionary

Not attached. I attest that all information will be provided where codes and/or value sets are needed (1.14a - 1.15c).

1.14 Numerator

Patients who received at least 135 days of treatment with beta-blockers during the 180-day measurement interval.

1.15 Denominator

An acute inpatient discharge from July 1 of the year prior to the measurement year through June 30 of the measurement year with any diagnosis of acute myocardial infarction (AMI) on the discharge claim.

1.20 Types of Data Sources

Claims Data

6.1.2 Current or Planned Use(s)

Public Reporting, Regulatory and Accreditation Programs, Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

6.1.3 Current Use(s)

Public Reporting, Regulatory and Accreditation Programs, Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

Exclusions

Any of the following any time during the patient's history through the end of the continuous enrollment period meet criteria:

- Asthma
- COPD
- Obstructive chronic bronchitis
- Chronic respiratory conditions due to fumes and vapors
- Hypotension, heart block >1 degree or sinus bradycardia
- A medication dispensing event indicative of a history of asthma
- Intolerance or allergy to beta-blocker therapy

Additionally, this measure excludes adults in hospice. It also excludes adults with advanced illness and frailty, as well as Medicare adults 65 years of age and older enrolled in an I-SNP or living long-term in institutional settings.

Measure Disclaimer

These performance measures are not clinical guidelines and do not establish a standard of medical care and have not been tested for all potential applications. THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

Risk Adjustment

No risk adjustment or risk stratification

Target Population

Populations at Risk

The measure developer is different from the measure steward

No

Steward Organization

National Committee for Quality Assurance

Steward POC email

measureendorsement@ncqa.org